MCID: SMT003
MIFTS: 53

Somatostatinoma

Categories: Rare diseases, Gastrointestinal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Somatostatinoma

MalaCards integrated aliases for Somatostatinoma:

Name: Somatostatinoma 38 12 76 53 59 55 44 15 73
Somatostatin-Secreting Pancreatic Neoplasm 53
Somatomedin-Secreting Carcinoid 53
Pancreatic Endocrine Carcinoma 73
Pancreatic Somatostatinoma 73
Somatostatin Cell Neoplasm 12
Malignant Islet Cell Tumor 53
Ampullary Somatostatinoma 53
Carcinoid Somatostatinoma 53
Somatostatin Cell Tumour 12

Characteristics:

Orphanet epidemiological data:

59
somatostatinoma
Prevalence: <1/1000000 (Europe); Age of onset: Adult;

Classifications:



Summaries for Somatostatinoma

MalaCards based summary : Somatostatinoma, also known as somatostatin-secreting pancreatic neoplasm, is related to pancreatic somatostatinoma and duodenal somatostatinoma, and has symptoms including diarrhea An important gene associated with Somatostatinoma is SST (Somatostatin), and among its related pathways/superpathways is Neuroscience. The drugs Bevacizumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and liver, and related phenotypes are diabetes mellitus and weight loss

Wikipedia : 76 Somatostatinoma is a malignant tumor of the delta cells of the endocrine pancreas that produces... more...

Related Diseases for Somatostatinoma

Diseases related to Somatostatinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Related Disease Score Top Affiliating Genes
1 pancreatic somatostatinoma 32.5 CALCA ENO2 SST
2 duodenal somatostatinoma 31.6 CALCA ENO2 INS SST
3 phaeochromocytoma 30.0 CHGA SST
4 paraganglioma 29.9 CHGA ENO2 SST
5 horseshoe kidney 29.8 CHGA ENO2
6 glucagonoma 29.4 CHGA SST VIP
7 carcinoid tumors, intestinal 29.3 CHGA ENO2 SST
8 merkel cell carcinoma 29.3 CHGA ENO2 SST
9 vipoma 29.1 CHGA SST VIP
10 multiple endocrine neoplasia 29.1 CALCA CHGA
11 gastrinoma 28.3 CHGA INS SST VIP
12 carcinoid syndrome 28.1 CALCA CHGA ENO2 SST
13 thyroid carcinoma, familial medullary 27.9 CALCA CHGA ENO2 SST
14 neuroendocrine tumor 27.8 CALCA CHGA ENO2 SST
15 islet cell tumor 27.1 CALCA CHGA INS SST VIP
16 pheochromocytoma 26.0 CALCA CHGA ENO2 EPAS1 SST VIP
17 jejunal somatostatinoma 11.9
18 multiple paragangliomas associated with polycythemia 11.2
19 pancreatic neuroendocrine tumor 11.0
20 postural hypotension 10.5 INS SST
21 hyperpituitarism 10.5 INS SST
22 dumping syndrome 10.5 INS SST
23 pancreatitis 10.5
24 vein disease 10.5 EPAS1 SST
25 gastrointestinal neuroendocrine benign tumor 10.5 CHGA SST
26 duodenitis 10.5
27 adenoma of the pancreas 10.5 CHGA SST
28 gastric neuroendocrine neoplasm 10.5 CHGA SST
29 retroperitoneal neuroblastoma 10.5 ENO2 SST
30 gastrointestinal neuroendocrine tumor 10.5 CHGA SST
31 pituitary carcinoma 10.5 CHGA SST
32 endocrine pancreas disease 10.4 INS SST
33 pituitary-dependent cushing's disease 10.4 INS SST
34 pancreatoblastoma 10.4 CHGA SST
35 zollinger-ellison syndrome 10.4 CHGA SST
36 pancreas disease 10.4 INS SST
37 duodenum cancer 10.4 ENO2 SST
38 pituitary gland disease 10.4 INS SST
39 hyperinsulinemic hypoglycemia 10.4 INS SST
40 small intestine cancer 10.3 ENO2 SST
41 serotonin syndrome 10.3 CHGA SST
42 retinal hemangioblastoma 10.3 ENO2 EPAS1
43 ureter small cell carcinoma 10.3 CHGA ENO2
44 urinary bladder small cell neuroendocrine carcinoma 10.3 CHGA ENO2
45 intracranial primitive neuroectodermal tumor 10.3 CHGA ENO2
46 secretory diarrhea 10.3 SST VIP
47 organ system benign neoplasm 10.3 ENO2 SST
48 cryptosporidiosis 10.3 SST VIP
49 auditory system cancer 10.3 CHGA ENO2
50 gallbladder small cell carcinoma 10.3 CHGA ENO2

Comorbidity relations with Somatostatinoma via Phenotypic Disease Network (PDN):


Pancreatic Cancer

Graphical network of the top 20 diseases related to Somatostatinoma:



Diseases related to Somatostatinoma

Symptoms & Phenotypes for Somatostatinoma

Human phenotypes related to Somatostatinoma:

59 32 (show all 36)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0000819
2 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
3 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
4 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
5 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
6 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
7 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
8 steatorrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002570
9 episodic abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002574
10 neoplasm of the pancreas 59 32 frequent (33%) Frequent (79-30%) HP:0002894
11 poor appetite 59 32 frequent (33%) Frequent (79-30%) HP:0004396
12 hypochromic microcytic anemia 59 32 frequent (33%) Frequent (79-30%) HP:0004840
13 gallbladder dysfunction 59 32 frequent (33%) Frequent (79-30%) HP:0005609
14 chronic fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012432
15 neoplasm of the small intestine 59 32 frequent (33%) Frequent (79-30%) HP:0100833
16 intermittent jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0001046
17 intrahepatic cholestasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001406
18 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
19 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
20 intestinal obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005214
21 extrahepatic cholestasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012334
22 lack of bowel sounds 59 32 occasional (7.5%) Occasional (29-5%) HP:0030145
23 increased circulating gonadotropin level 59 32 very rare (1%) Very rare (<4-1%) HP:0000837
24 growth hormone excess 59 32 very rare (1%) Very rare (<4-1%) HP:0000845
25 prolactin excess 59 32 very rare (1%) Very rare (<4-1%) HP:0000870
26 subcutaneous lipoma 59 32 very rare (1%) Very rare (<4-1%) HP:0001031
27 medullary thyroid carcinoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002865
28 pituitary adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002893
29 parathyroid adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002897
30 hypercalcemia 59 32 very rare (1%) Very rare (<4-1%) HP:0003072
31 primary hyperparathyroidism 59 32 very rare (1%) Very rare (<4-1%) HP:0008200
32 adrenocortical adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0008256
33 abnormality of the abdomen 59 Occasional (29-5%)
34 abnormality of the thyroid gland 59 Very rare (<4-1%)
35 hypercortisolism 59 Very rare (<4-1%)
36 increased circulating cortisol level 32 very rare (1%) HP:0003118

UMLS symptoms related to Somatostatinoma:


diarrhea

Drugs & Therapeutics for Somatostatinoma

Drugs for Somatostatinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
4
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
8 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
9 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
10 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
11 Antimetabolites Phase 2, Phase 3,Phase 1
12 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
13 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
14 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
15 Adjuvants, Anesthesia Phase 3
16 Analgesics Phase 3
17 Analgesics, Opioid Phase 3
18 Anesthetics Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Central Nervous System Depressants Phase 3
22 Narcotics Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
28
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
29
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
30
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
31
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
32
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
33
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
34
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
35
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
36
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
37
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
38
Octreotide Approved, Investigational Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40
Pancrelipase Approved, Investigational Phase 2 53608-75-6
41
Melphalan Approved Phase 2 148-82-3 4053 460612
42
Somatostatin Approved, Investigational Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
43
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
44
Gemcitabine Approved Phase 2 95058-81-4 60750
45
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
46
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
47
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
49
Vatalanib Investigational Phase 2,Phase 1 212141-54-3 151194
50 Micronutrients Phase 2

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
4 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
5 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
6 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
7 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
8 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
9 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
10 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
11 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
12 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
13 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
14 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
15 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
16 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
17 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
18 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
19 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
20 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2 Bortezomib;Panobinostat
21 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
22 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
23 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
24 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
25 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
26 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
27 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
28 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
29 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
30 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
31 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
32 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
33 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
34 Ga-DOTATOC Versus Octreoscan + CT Suspended NCT01869725 Not Applicable
35 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Terminated NCT00730483 Not Applicable PVA microporous hydrospheres/doxorubicin hydrochloride

Search NIH Clinical Center for Somatostatinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: somatostatinoma

Genetic Tests for Somatostatinoma

Anatomical Context for Somatostatinoma

MalaCards organs/tissues related to Somatostatinoma:

41
Pancreas, Liver, Thyroid, Kidney, Endothelial, Pituitary, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Somatostatinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Head of Pancreas Affected by disease

Publications for Somatostatinoma

Articles related to Somatostatinoma:

(show top 50) (show all 193)
# Title Authors Year
1
Somatostatinoma Masquerading as Chronic Pancreatitis. ( 29521948 )
2018
2
Mixed mucinous adenocarcinoma and somatostatinoma of the ampulla of Vater associated with neurofibromatosis type 1. ( 28693748 )
2017
3
The Coexistence of Somatostatinoma and Gastrointestinal Stromal Tumor in the Duodenum of a Patient with Von Recklinghausen's Disease. ( 26984078 )
2016
4
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. ( 27160433 )
2016
5
Combined presence of multiple gastrointestinal stromal tumors along with duodenal submucosal somatostatinoma in a patient with neurofibromatosis type 1. ( 27510677 )
2016
6
Somatostatinoma of the minor duodenal papilla associated with pancreas divisum treated by endoscopic papillectomy. ( 27078626 )
2016
7
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. ( 27679736 )
2016
8
Somatostatinoma of the Ampulla: An Incidental Postoperative Finding Following Colorectal Cancer Resection. ( 26958562 )
2016
9
Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. ( 27081557 )
2015
10
Somatostatinoma of the minor papilla treated by local excision in a patient with neurofibromatosis type 1. ( 25640791 )
2015
11
Pancreatic somatostatinoma diagnosed preoperatively: report of a case. ( 24413789 )
2014
12
Mixed periampullary adenocarcinoma and somatostatinoma with small bowel gastrointestinal stromal tumour in neurofibromatosis type 1. ( 25435578 )
2014
13
Education and imaging. Gastrointestinal: neurofibromatosis type 1, duodenal somatostatinoma and gastrointestinal stromal tumors; a triad worth remembering. ( 24646427 )
2014
14
Ocular Manifestations of Hypoxia-Inducible Factor-2I+ Paraganglioma-Somatostatinoma-Polycythemia Syndrome. ( 25109928 )
2014
15
Endoscopic ultrasound-guided fine-needle aspiration diagnosis of mixed endocrine somatostatinoma of the minor papilla in von Recklinghausen disease. ( 25526415 )
2014
16
Gastric somatostatinoma: an extremely rare cause of upper gastrointestinal bleeding. ( 24143326 )
2013
17
Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. ( 23361906 )
2013
18
Patient with adult-onset type II citrullinemia beginning 2 years after operation for duodenal malignant somatostatinoma: Indication for liver transplantation. ( 23617280 )
2013
19
Duodenal somatostatinoma: a case report and review of the literature. ( 23618063 )
2013
20
New syndrome of paraganglioma and somatostatinoma associated with polycythemia. ( 23509317 )
2013
21
Case report: recurrent acute pancreatitis secondary to papillary somatostatinoma--a new association. ( 23561978 )
2013
22
Quantum dot immunocytochemical localization of somatostatin in somatostatinoma by Widefield Epifluorescence, super-resolution light, and immunoelectron microscopy. ( 22899862 )
2012
23
Persistent severe gastrointestinal bleeding in a man with metastatic somatostatinoma. ( 21940726 )
2012
24
Endoscopic submucosal dissection of solitary duodenal somatostatinoma (with video). ( 22018555 )
2012
25
Double somatostatinoma and double papillectomy in a patient with type 1 neurofibromatosis (von Recklinghausen's disease). ( 23012013 )
2012
26
Somatostatinoma of the first jejunal loop in a patient with neurofibromatosis von Recklinghausen and bilateral pheochromocytoma. ( 22819908 )
2012
27
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. ( 21831734 )
2011
28
Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. ( 21868544 )
2011
29
Duodenal somatostatinoma: a case report and review. ( 21437171 )
2011
30
Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern. ( 20043348 )
2010
31
Cardiac metastasis from malignant pancreatic somatostatinoma. ( 19733881 )
2010
32
Pancreatic endocrine carcinoma protruding from the major papilla. ( 20144741 )
2010
33
Hypercalcitonemia revealing a somatostatinoma. ( 20817146 )
2010
34
Asymptomatic somatostatinoma of the pancreatic head: Report of a case. ( 20496141 )
2010
35
Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome: pathophysiologic considerations. ( 20497932 )
2010
36
Mixed endocrine somatostatinoma of the ampulla of vater associated with a neurofibromatosis type 1: a case report and review of the literature. ( 20065557 )
2010
37
Pancreatic somatostatinoma with von Recklinghausen's disease. ( 18926936 )
2009
38
Association of GIST and somatostatinoma in a patient with type-1 neurofibromatosis: is there a common pathway? ( 19223891 )
2009
39
Pancreatic somatostatinoma characterized by extreme hypoglycemia. ( 19719976 )
2009
40
Pancreatic somatostatinoma manifested as severe hypoglycemia. ( 19565056 )
2009
41
A large functional somatostatinoma in the pancreatic tail: atypical CT appearances. ( 20084576 )
2009
42
Two synchronous somatostatinomas of the duodenum and pancreatic head in one patient. ( 19998510 )
2009
43
Pancreatic somatostatinoma and tuberous sclerosis: case report of an exceedingly rare association. ( 18672238 )
2009
44
Clinical challenges and images in GI. Ampullary somatostatinoma associated with neurofibromatosis type 1, presenting with iron-deficiency anemia. ( 19063889 )
2009
45
FNAC diagnosis of pancreatic somatostatinoma. ( 21938182 )
2009
46
Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas. ( 18795665 )
2008
47
A case of multiple hepatic metastases from pancreatic endocrine carcinoma. ( 18573853 )
2008
48
Diagnosis and treatment of pancreatic somatostatinoma: a case report. ( 19080351 )
2008
49
Somatostatinoma: clinico-pathological features of three cases and literature reviewed. ( 17645474 )
2008
50
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. ( 18362846 )
2008

Variations for Somatostatinoma

Expression for Somatostatinoma

Search GEO for disease gene expression data for Somatostatinoma.

Pathways for Somatostatinoma

Pathways related to Somatostatinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.33 CALCA ENO2 VIP

GO Terms for Somatostatinoma

Cellular components related to Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.55 CALCA CHGA INS SST VIP
2 neuronal cell body GO:0043025 9.13 CALCA ENO2 SST
3 extracellular space GO:0005615 9.02 CALCA CHGA ENO2 INS SST

Biological processes related to Somatostatinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.76 CALCA INS SST VIP
2 cell-cell signaling GO:0007267 9.58 CALCA INS SST
3 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.49 CALCA VIP
4 regulation of blood pressure GO:0008217 9.48 CALCA CHGA
5 regulation of protein localization GO:0032880 9.43 INS VIP
6 response to heat GO:0009408 9.37 CALCA SST
7 regulation of heart rate GO:0002027 9.32 CALCA EPAS1
8 positive regulation of blood vessel diameter GO:0097755 9.26 CALCA INS
9 regulation of signaling receptor activity GO:0010469 9.26 CALCA INS SST VIP
10 positive regulation of cAMP metabolic process GO:0030816 9.16 CALCA CHGA
11 negative regulation of blood vessel diameter GO:0097756 8.62 CHGA INS

Molecular functions related to Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 CALCA INS SST VIP

Sources for Somatostatinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....